BioCentury
ARTICLE | Clinical News

Otezla apremilast: Additional Phase III data

April 7, 2014 7:00 AM UTC

Additional data from the double-blind, international Phase III ESTEEM 2 trial in 413 patients with moderate to severe plaque psoriasis showed that twice-daily 30 mg Otezla led to a PASI 75 response rate, the primary endpoint, at week 16 of 28.8% vs. 5.8% for placebo (p<0.0001). On secondary endpoints, a significantly greater proportion of patients receiving Otezla achieved an sPGA score of "clear" or "almost clear" at week 16 vs. placebo (20.4% vs. 4.4%, p<0.0001). Otezla also led to a significantly greater PASI 50 response rate at week 16 vs. placebo (55.5% vs. 19.7%, p<0.0001). Additionally, Otezla led to significantly higher response rates vs. placebo for psoriasis affecting the scalp (40.9% vs. 17.2%, p<0.0001), nails (44.6% vs. 18.7%, p<0.0001) and palm and soles (65.4% vs. 31.3%, p=0.0315). Data were presented at the American Academy of Dermatology meeting in Denver. ...